Protease-activated receptor-2 modulates myocardial ischemia-reperfusion injury in the rat heart.

Protease-activated receptor-2 (PAR-2) is a member of seven transmembrane domain G protein-coupled receptors activated by proteolytic cleavage whose better known member is the thrombin receptor. The pathophysiological role of PAR-2 remains poorly understood. Because PAR-2 is involved in inflammatory and injury response events, we investigated the role of PAR-2 in experimental myocardial ischemia-reperfusion injury. We show for the first time that PAR-2 activation protects against reperfusion-injury. After PAR-2-activating peptide (2AP) infusion, we found a significant recovery of myocardial function and decrease in oxidation at reflow. Indeed, the glutathione cycle (glutathione and oxidized glutathione) and lipid peroxidation analysis showed a reduced oxidative reperfusion-injury. Moreover, ischemic risk zone and creatine kinase release were decreased after PAR-2AP treatment. These events were coupled to elevation of PAR-2 and tumor necrosis factor alpha (TNFalpha) expression in both nuclear extracts and whole heart homogenates. The recovery of coronary flow was not reverted by L-nitroarginine methylester, indicating a NO-independent pathway for this effect. Genistein, a tyrosine kinase inhibitor, did not revert the PAR-2AP effect. During early reperfusion injury in vivo not only oxygen radicals are produced but also numerous proinflammatory mediators promoting neutrophil and monocyte targeting. In this context, we show that TNFalpha and PAR-2 are involved in signaling in pathophysiological conditions, such as myocardial ischemia-reperfusion. At the same time, because TNFalpha may exert pro-inflammatory actions and PAR-2 may constitute one of the first protective mechanisms that signals a primary inflammatory response, our data support the concept that this network may regulate body responses to tissue injury.

[1]  C. Sobey,et al.  Evidence for selective effects of chronic hypertension on cerebral artery vasodilatation to protease-activated receptor-2 activation. , 1999, Stroke.

[2]  J. Wallace,et al.  Characterization of the inflammatory response to proteinase‐activated receptor‐2 (PAR2)‐activating peptides in the rat paw , 1999, British journal of pharmacology.

[3]  M. Hollenberg Protease-activated receptors: PAR4 and counting: how long is the course? , 1999, Trends in pharmacological sciences.

[4]  J. Mehta,et al.  Kinetics of tumor necrosis factor α in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor α in acute myocardial infarction , 1999 .

[5]  A. Harken,et al.  Inhibition of Myocardial TNF‐α Production by Heat Shock: A Potential Mechanism of Stress‐Induced Cardioprotection against Postischemic Dysfunction a , 1999, Annals of the New York Academy of Sciences.

[6]  R. Sorrentino,et al.  Protease-activated receptor-2 involvement in hypotension in normal and endotoxemic rats in vivo. , 1999, Circulation.

[7]  M. Carr,et al.  A protective role for protease-activated receptors in the airways , 1999, Nature.

[8]  S. Zahler,et al.  Tumor necrosis factor-alpha contributes to ischemia- and reperfusion-induced endothelial activation in isolated hearts. , 1999, Circulation research.

[9]  W. Fung-Leung,et al.  Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1. , 1999, The Journal of pharmacology and experimental therapeutics.

[10]  C. Napoli,et al.  Age-related decrease in cardiac tolerance to oxidative stress. , 1999, Journal of molecular and cellular cardiology.

[11]  T. Minami,et al.  Increased vascular permeability by a specific agonist of protease‐activated receptor‐2 in rat hindpaw , 1998, British journal of pharmacology.

[12]  C. Sobey,et al.  Activation of protease-activated receptor-2 (PAR-2) elicits nitric oxide-dependent dilatation of the basilar artery in vivo. , 1998, Stroke.

[13]  J. Hamilton,et al.  Atypical protease-activated receptor mediates endothelium-dependent relaxation of human coronary arteries. , 1998, Circulation research.

[14]  J. Hoxie,et al.  Differential expression of functional protease-activated receptor-2 (PAR-2) in human vascular smooth muscle cells. , 1998, Arteriosclerosis, Thrombosis and Vascular Biology.

[15]  D. Mann,et al.  Tumor Necrosis Factor- (cid:97) Confers Resistance to Hypoxic Injury in the Adult Mammalian Cardiac Myocyte , 2022 .

[16]  C. Napoli,et al.  New-onset angina preceding acute myocardial infarction is associated with improved contractile recovery after thrombolysis. , 1998, European heart journal.

[17]  S. M. Baker,et al.  Characterization of Protease-activated Receptor-2 Immunoreactivity in Normal Human Tissues , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[18]  C. Derian,et al.  Receptor-activating peptides distinguish thrombin receptor (PAR-1) and protease activated receptor 2 (PAR-2) mediated hemodynamic responses in vivo. , 1998, Canadian journal of physiology and pharmacology.

[19]  B. Walker,et al.  Identification of potential activators of proteinase‐activated receptor‐2 1 , 1997, FEBS letters.

[20]  D. Payan,et al.  Mast cell tryptase regulates rat colonic myocytes through proteinase-activated receptor 2. , 1997, The Journal of clinical investigation.

[21]  J. Danesh,et al.  Chronic infections and coronary heart disease: is there a link? , 1997, The Lancet.

[22]  M. Hollenberg,et al.  Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Wahlestedt,et al.  Vascular effects of proteinase-activated receptor 2 agonist peptide. , 1997, Journal of vascular research.

[24]  C. Napoli,et al.  A simple and rapid purification procedure minimizes spontaneous oxidative modifications of low density lipoprotein and lipoprotein (a). , 1997, Journal of biochemistry.

[25]  P. Renesto,et al.  Specific inhibition of thrombin-induced cell activation by the neutrophil proteinases elastase, cathepsin G, and proteinase 3: evidence for distinct cleavage sites within the aminoterminal domain of the thrombin receptor. , 1997, Blood.

[26]  J. Hoxie,et al.  Interactions of Mast Cell Tryptase with Thrombin Receptors and PAR-2* , 1997, The Journal of Biological Chemistry.

[27]  V. Ramakrishnan,et al.  The Proteinase-activated Receptor 2 Is Induced by Inflammatory Mediators in Human Endothelial Cells , 1996, The Journal of Biological Chemistry.

[28]  M. Hollenberg,et al.  Rat proteinase‐activated receptor‐2 (PAR‐2): cDNA sequence and activity of receptor‐derived peptides in gastric and vascular tissue , 1996, British journal of pharmacology.

[29]  Meeta Chatterjee,et al.  Evidence for the presence of a proteinase-activated receptor distinct from the thrombin receptor in vascular endothelial cells. , 1996, Circulation research.

[30]  G. Wong,et al.  Leukemia inhibitory factor and tumor necrosis factor induce manganese superoxide dismutase and protect rabbit hearts from reperfusion injury. , 1995, Journal of molecular and cellular cardiology.

[31]  C. Wahlestedt,et al.  Molecular cloning of a potential proteinase activated receptor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  N. Tsuji,et al.  Endogenous tumor necrosis factor exerts its protective function intracellularly against the cytotoxicity of exogenous tumor necrosis factor. , 1992, Cancer research.

[33]  G. Wong,et al.  Tumor necrosis factor-α pretreatment is protective in a rat model of myocardial ischemia-reperfusion injury , 1992 .

[34]  H. Langstein,et al.  Single-dose tumor necrosis factor protection against endotoxin-induced shock and tissue injury in rats , 1991, Infection and immunity.

[35]  A. A. Taylor,et al.  Inflammation in the course of early myocardial ischemia , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  M. Weisfeldt,et al.  Measurement and characterization of postischemic free radical generation in the isolated perfused heart. , 1989, The Journal of biological chemistry.

[37]  A. Harken,et al.  Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Goeddel,et al.  Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism , 1988, Science.

[39]  L. Becker,et al.  Myocardial consequences of reperfusion. , 1987, Progress in cardiovascular diseases.

[40]  H. Sies,et al.  Energy‐linked cardiac transport system for glutathione disulfide , 1986, FEBS letters.

[41]  Carl Wu An exonuclease protection assay reveals heat-shock element and TATA box DNA-binding proteins in crude nuclear extracts , 1985, Nature.

[42]  T. Ishikawa,et al.  Cardiac transport of glutathione disulfide and S-conjugate. Studies with isolated perfused rat heart during hydroperoxide metabolism. , 1984, The Journal of biological chemistry.

[43]  L. Harker,et al.  Glutathione redox cycle protects cultured endothelial cells against lysis by extracellularly generated hydrogen peroxide. , 1984, The Journal of clinical investigation.

[44]  T. Slater Overview of methods used for detecting lipid peroxidation. , 1984, Methods in enzymology.

[45]  B Chance,et al.  Hydroperoxide metabolism in mammalian organs. , 1979, Physiological reviews.

[46]  J. McCord Free Radicals and Inflammation: Protection of Synovial Fluid by Superoxide Dismutase , 1974, Science.

[47]  F. Tietze Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. , 1969, Analytical biochemistry.

[48]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.